BNTC

BNTC

USD

Benitec Biopharma Inc. Common Stock

$15.710+0.380 (2.479%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$15.330

最高价

$15.770

最低价

$14.550

成交量

0.13M

公司基本面

市值

412.4M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.05M

交易所

NCM

货币

USD

52周价格范围

最低价 $9.1当前价 $15.710最高价 $17.15

相关新闻

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.

查看更多
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
Analyst Upgrades

Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.

查看更多
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted

查看更多
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based

查看更多
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines

查看更多
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy